Who is sponsoring NCT02119858?

NCT02119858 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT02119858?

Interventions in NCT02119858: indocyanine green solution, diffuse optical imaging, robot-assisted laparoscopic surgery, therapeutic lymphadenectomy.

What condition does NCT02119858 study?

NCT02119858 studies Stage IIA Prostate Cancer, Stage IIB Prostate Cancer.

Is NCT02119858 still recruiting?

NCT02119858 is currently completed. Last updated 22 February 2018.

Last reviewed 2018-02-22 · How we verify

NCT02119858

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery

Completed Phase 1 Last updated 22 February 2018

What this trial tests

Phase 1 trial testing indocyanine green solution in Stage IIA Prostate Cancer in 20 participants. Completed in 7 February 2018.

Timeline

25 July 2014

Primary endpoint
7 February 2018

7 February 2018

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	25 July 2014
Primary completion	7 February 2018
Estimated completion	7 February 2018
Sites	1 location across United States

Drugs / interventions tested

indocyanine green solution — full drug profile →
diffuse optical imaging
robot-assisted laparoscopic surgery
therapeutic lymphadenectomy

Conditions studied

Stage IIA Prostate Cancer — all drugs for Stage IIA Prostate Cancer →
Stage IIB Prostate Cancer — all drugs for Stage IIB Prostate Cancer →

Sponsor

City of Hope Medical Center

Who can join

Adults 18 to 80, male only, with Stage IIA Prostate Cancer or Stage IIB Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial studies diffuse optical imaging with indocyanine green solution in imaging pelvic lymph nodes in patients with stage II prostate cancer undergoing surgery. Indocyanine green solution is a special dye that can help doctors see the lymph nodes and blood vessels during surgery when visualized under diffuse optical imaging. Indocyanine green solution may improve the ability to detect lymph nodes and may lead to improved accuracy of lymph node removal.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation.
Olson MT, Ly QP, Mohs AM. · · 2019 · cited 48× · PMID 29942988 · DOI 10.1007/s11307-018-1239-2

Verify or expand the search:

Other recruiting trials for Stage IIA Prostate Cancer

Currently open trials in the same condition.

NCT03880422 — Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer S · NA · recruiting
NCT02346253 — High-Dose Brachytherapy in Treating Patients With Prostate Cancer · NA · active not recruiting
NCT02176902 — Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer · NA · active not recruiting
NCT01923506 — Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery · Phase 1 · active not recruiting
NCT01655836 — High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer · Phase 1 · active not recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02119858 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 22 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02119858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing